Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10549-011-1766-x.

Title:
The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin | Breast Cancer Research and Treatment
Description:
Tamoxifen resistance has been largely attributed to genetic alterations in the epithelial tumor cells themselves, such as overexpression of HER-2/Neu. However, in the clinic, only about 15–20% of cases of HER-2/Neu amplification has actually been correlated to the acquisition of endocrine resistance, suggesting that other mechanisms must be involved as well. Using the epithelial LM05-E and the fibroblastic LM05-F cell lines, derived from the estrogen dependent spontaneous M05 mouse mammary tumor, as well as MCF-7 cells, we analyzed whether soluble stromal factors or extracellular matrix components protected against tamoxifen induced cell death. Involvement of signaling pathways was determined by using specific inhibitors and western blot, and phosphorylation of the estrogen receptor alpha by western blot and immunofluorescence. Soluble factors produced by the fibroblastic cells protect the epithelial tumor cells from tamoxifen-induced cell death through a mechanism that involves EGFR and matrix metalloproteinases upstream of PI3K/AKT. Exogenous fibronectin by itself confers endocrine resistance through interaction with β1 integrin and activation of PI3K/AKT and MAPK/ERK 1/2 pathways. The conferred resistance is reversed by blocking β1 integrin. We show also that treatment with both conditioned medium and fibronectin leads to the phosphorylation of the estrogen receptor at serine-118, suggesting stromal factors as modulators of ER activity. Our results show that the tumor microenvironment can modulate tamoxifen resistance, providing an alternative explanation for why patients become refractory to hormone-therapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cancer, article, pubmed, cas, google, scholar, breast, resistance, cells, estrogen, matrix, tumor, tamoxifen, res, receptor, integrin, cell, clin, research, epithelial, endocrine, stromal, factors, fibronectin, bissell, simian, mammary, extracellular, growth, signaling, therapy, factor, human, privacy, cookies, content, microenvironment, soluble, kier, access, molecular, inhibitor, information, publish, search, role, pontiggia, raffo, mechanisms, death,

Topics {✒️}

month download article/chapter de kier joff� tamoxifen-resistant breast cancer tamoxifen-resistant breast carcinomas matrix metalloproteinase-1-dependent invasion tamoxifen-induced cell death small-cell lung cancer soluble stromal factors spontaneous estrogen dependent mapk/erk inhibitor pd98059 mammary epithelial cells tumor microenvironment stromal-epithelial interactions blocking β1 integrin soluble factors produced pi3k/akt inhibitor ly294002 epithelial tumor cells breast cancer cells estrogen receptor alpha full article pdf marina simian growth factor signalling human breast cancer advanced breast cancer breast cancer prognosis invasive breast cancer protects tumor cells breast tumor fibroblasts suggesting stromal factors modulate tamoxifen resistance mesenchymal conversion increased beta1 integrin privacy choices/manage cookies breast cancer progression related subjects gutierrez mc stromal cellular responses de-ac02-05ch1123 integrin fibronectin receptors understand estrogen responsiveness endocrine-sensitive cells health effects division epithelial cell morphology β1 integrin mapk/erk 1/2 pathways gene expression profiling confers endocrine resistance article pontiggia selective estrogen modulators extracellular matrix regulation

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin
         description:Tamoxifen resistance has been largely attributed to genetic alterations in the epithelial tumor cells themselves, such as overexpression of HER-2/Neu. However, in the clinic, only about 15–20% of cases of HER-2/Neu amplification has actually been correlated to the acquisition of endocrine resistance, suggesting that other mechanisms must be involved as well. Using the epithelial LM05-E and the fibroblastic LM05-F cell lines, derived from the estrogen dependent spontaneous M05 mouse mammary tumor, as well as MCF-7 cells, we analyzed whether soluble stromal factors or extracellular matrix components protected against tamoxifen induced cell death. Involvement of signaling pathways was determined by using specific inhibitors and western blot, and phosphorylation of the estrogen receptor alpha by western blot and immunofluorescence. Soluble factors produced by the fibroblastic cells protect the epithelial tumor cells from tamoxifen-induced cell death through a mechanism that involves EGFR and matrix metalloproteinases upstream of PI3K/AKT. Exogenous fibronectin by itself confers endocrine resistance through interaction with β1 integrin and activation of PI3K/AKT and MAPK/ERK 1/2 pathways. The conferred resistance is reversed by blocking β1 integrin. We show also that treatment with both conditioned medium and fibronectin leads to the phosphorylation of the estrogen receptor at serine-118, suggesting stromal factors as modulators of ER activity. Our results show that the tumor microenvironment can modulate tamoxifen resistance, providing an alternative explanation for why patients become refractory to hormone-therapy.
         datePublished:2011-09-21T00:00:00Z
         dateModified:2011-09-21T00:00:00Z
         pageStart:459
         pageEnd:471
         sameAs:https://doi.org/10.1007/s10549-011-1766-x
         keywords:
            Breast cancer
            Tamoxifen resistance
            Estrogen receptor
            Tumor microenvironment
            Fibronectin
            Soluble stromal factors
            β1 integrin
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig7_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig8_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:133
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Osvaldo Pontiggia
               affiliation:
                     name:Instituto de Oncología “Ángel H. Roffo”
                     address:
                        name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rocio Sampayo
               affiliation:
                     name:Instituto de Oncología “Ángel H. Roffo”
                     address:
                        name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Diego Raffo
               affiliation:
                     name:Instituto de Oncología “Ángel H. Roffo”
                     address:
                        name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Andrea Motter
               affiliation:
                     name:Instituto de Oncología “Ángel H. Roffo”
                     address:
                        name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ren Xu
               affiliation:
                     name:Lawrence Berkeley National Laboratory
                     address:
                        name:Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Kentucky
                     address:
                        name:Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mina J. Bissell
               affiliation:
                     name:Lawrence Berkeley National Laboratory
                     address:
                        name:Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elisa Bal de Kier Joffé
               affiliation:
                     name:Instituto de Oncología “Ángel H. Roffo”
                     address:
                        name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marina Simian
               affiliation:
                     name:Instituto de Oncología “Ángel H. Roffo”
                     address:
                        name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin
      description:Tamoxifen resistance has been largely attributed to genetic alterations in the epithelial tumor cells themselves, such as overexpression of HER-2/Neu. However, in the clinic, only about 15–20% of cases of HER-2/Neu amplification has actually been correlated to the acquisition of endocrine resistance, suggesting that other mechanisms must be involved as well. Using the epithelial LM05-E and the fibroblastic LM05-F cell lines, derived from the estrogen dependent spontaneous M05 mouse mammary tumor, as well as MCF-7 cells, we analyzed whether soluble stromal factors or extracellular matrix components protected against tamoxifen induced cell death. Involvement of signaling pathways was determined by using specific inhibitors and western blot, and phosphorylation of the estrogen receptor alpha by western blot and immunofluorescence. Soluble factors produced by the fibroblastic cells protect the epithelial tumor cells from tamoxifen-induced cell death through a mechanism that involves EGFR and matrix metalloproteinases upstream of PI3K/AKT. Exogenous fibronectin by itself confers endocrine resistance through interaction with β1 integrin and activation of PI3K/AKT and MAPK/ERK 1/2 pathways. The conferred resistance is reversed by blocking β1 integrin. We show also that treatment with both conditioned medium and fibronectin leads to the phosphorylation of the estrogen receptor at serine-118, suggesting stromal factors as modulators of ER activity. Our results show that the tumor microenvironment can modulate tamoxifen resistance, providing an alternative explanation for why patients become refractory to hormone-therapy.
      datePublished:2011-09-21T00:00:00Z
      dateModified:2011-09-21T00:00:00Z
      pageStart:459
      pageEnd:471
      sameAs:https://doi.org/10.1007/s10549-011-1766-x
      keywords:
         Breast cancer
         Tamoxifen resistance
         Estrogen receptor
         Tumor microenvironment
         Fibronectin
         Soluble stromal factors
         β1 integrin
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig7_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1766-x/MediaObjects/10549_2011_1766_Fig8_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:133
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Osvaldo Pontiggia
            affiliation:
                  name:Instituto de Oncología “Ángel H. Roffo”
                  address:
                     name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rocio Sampayo
            affiliation:
                  name:Instituto de Oncología “Ángel H. Roffo”
                  address:
                     name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Diego Raffo
            affiliation:
                  name:Instituto de Oncología “Ángel H. Roffo”
                  address:
                     name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Andrea Motter
            affiliation:
                  name:Instituto de Oncología “Ángel H. Roffo”
                  address:
                     name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ren Xu
            affiliation:
                  name:Lawrence Berkeley National Laboratory
                  address:
                     name:Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Kentucky
                  address:
                     name:Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mina J. Bissell
            affiliation:
                  name:Lawrence Berkeley National Laboratory
                  address:
                     name:Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elisa Bal de Kier Joffé
            affiliation:
                  name:Instituto de Oncología “Ángel H. Roffo”
                  address:
                     name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marina Simian
            affiliation:
                  name:Instituto de Oncología “Ángel H. Roffo”
                  address:
                     name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:133
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Instituto de Oncología “Ángel H. Roffo”
      address:
         name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
         type:PostalAddress
      name:Instituto de Oncología “Ángel H. Roffo”
      address:
         name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
         type:PostalAddress
      name:Instituto de Oncología “Ángel H. Roffo”
      address:
         name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
         type:PostalAddress
      name:Instituto de Oncología “Ángel H. Roffo”
      address:
         name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
         type:PostalAddress
      name:Lawrence Berkeley National Laboratory
      address:
         name:Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:Lawrence Berkeley National Laboratory
      address:
         name:Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA
         type:PostalAddress
      name:Instituto de Oncología “Ángel H. Roffo”
      address:
         name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
         type:PostalAddress
      name:Instituto de Oncología “Ángel H. Roffo”
      address:
         name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Osvaldo Pontiggia
      affiliation:
            name:Instituto de Oncología “Ángel H. Roffo”
            address:
               name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
               type:PostalAddress
            type:Organization
      name:Rocio Sampayo
      affiliation:
            name:Instituto de Oncología “Ángel H. Roffo”
            address:
               name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
               type:PostalAddress
            type:Organization
      name:Diego Raffo
      affiliation:
            name:Instituto de Oncología “Ángel H. Roffo”
            address:
               name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
               type:PostalAddress
            type:Organization
      name:Andrea Motter
      affiliation:
            name:Instituto de Oncología “Ángel H. Roffo”
            address:
               name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
               type:PostalAddress
            type:Organization
      name:Ren Xu
      affiliation:
            name:Lawrence Berkeley National Laboratory
            address:
               name:Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA
               type:PostalAddress
            type:Organization
            name:University of Kentucky
            address:
               name:Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      name:Mina J. Bissell
      affiliation:
            name:Lawrence Berkeley National Laboratory
            address:
               name:Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA
               type:PostalAddress
            type:Organization
      name:Elisa Bal de Kier Joffé
      affiliation:
            name:Instituto de Oncología “Ángel H. Roffo”
            address:
               name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
               type:PostalAddress
            type:Organization
      name:Marina Simian
      affiliation:
            name:Instituto de Oncología “Ángel H. Roffo”
            address:
               name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
      name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
      name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
      name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
      name:Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA
      name:Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, USA
      name:Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA
      name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
      name:Área de Investigaciones, Instituto de Oncología “Ángel H. Roffo”, Buenos Aires, Argentina
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(147)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.32s.